| Suspended | Woodsmoke Exposure, Influenza Infection, and Nasal Immunity NCT06841913 | University of North Carolina, Chapel Hill | Phase 4 |
| Not Yet Recruiting | H1ssF Flu Vaccine Clinical Trial NCT07340047 | University of Minnesota | Phase 1 |
| Recruiting | BPL-1357 Against H1N1 Influenza Virus Challenge NCT07215858 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Not Yet Recruiting | Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model NCT07503405 | Traws Pharma, Inc. | Phase 2 |
| Not Yet Recruiting | Study to Investigate the Efficacy and Safety of Apomivir® NCT01677689 | Far East Bio-Tec Co., Ltd | Phase 2 |
| Not Yet Recruiting | Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), F NCT07149428 | National Institute on Deafness and Other Communication Disorders (NIDCD) | — |
| Not Yet Recruiting | Noseguard for Prevention of Respiratory Infections in Real-World Use NCT07516977 | Daewoong Pharmaceutical Co. LTD. | N/A |
| Recruiting | A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults NCT07496450 | ModernaTX, Inc. | Phase 3 |
| Not Yet Recruiting | Effect of Oral Supplement on Influenza Vaccine Long-term Response NCT07357467 | Tsinghua University | — |
| Recruiting | Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine NCT07291635 | Aramis Biotechnologies Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant) NCT07349017 | Changchun BCHT Biotechnology Co. | Phase 1 |
| Not Yet Recruiting | Adaptive RCT of Corticosteroids for Severe Influenza Pneumonia in Adults NCT07351500 | Qingyuan Zhan | Phase 3 |
| Not Yet Recruiting | Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above NCT07327398 | Shanghai Institute Of Biological Products | Phase 2 |
| Recruiting | A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above NCT07302256 | Shanghai Institute Of Biological Products | Phase 1 |
| Active Not Recruiting | This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patient NCT07371650 | Traws Pharma, Inc. | Phase 2 |
| Recruiting | Immune Defense Protein Impact On Respiratory Immune Outcomes NCT07431840 | Quantec Ltd | N/A |
| Recruiting | Influenza Vaccination Strategy for Patients With Hematologic Malignancy NCT07485855 | Asan Medical Center | Phase 3 |
| Active Not Recruiting | Post-exposure Influenza Prophylaxis in a Hospital Setting NCT07496736 | University Medical Centre Ljubljana | Phase 3 |
| Not Yet Recruiting | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety an NCT07229547 | Ruijin Hospital | Phase 3 |
| Recruiting | Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting NCT07236814 | Capital Medical University | Phase 3 |
| Active Not Recruiting | Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Ol NCT07421037 | Ab&B Bio-tech Co., Ltd.JS | Phase 1 |
| Active Not Recruiting | Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older NCT07421050 | Ab&B Bio-tech Co., Ltd.JS | Phase 1 |
| Recruiting | Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study NCT07287137 | Henry M. Jackson Foundation for the Advancement of Military Medicine | Phase 4 |
| Recruiting | Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) a NCT07420985 | Valenta Pharm JSC | Phase 2 |
| Recruiting | Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women NCT07211152 | Sinovac Biotech Co., Ltd | Phase 3 |
| Active Not Recruiting | Mucosal and Systemic Immune Responses Induced by an Intranasal Influenza Live Attenuated Vaccine NCT07232745 | Jiangsu Province Centers for Disease Control and Prevention | Phase 4 |
| Active Not Recruiting | Kaiser Colorado Flu Nudge NCT07372950 | Kaiser Permanente | N/A |
| Recruiting | The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study NCT07240922 | The University of Hong Kong | Phase 4 |
| Not Yet Recruiting | Effectiveness of SMS Nudging to Increase Coverage of Influenza Vaccination Among the Elderly NCT06486766 | Norwegian Institute of Public Health | N/A |
| Active Not Recruiting | A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza NCT07159763 | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 |
| Recruiting | High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) NCT07192458 | Vanderbilt University Medical Center | Phase 2 |
| Recruiting | First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics NCT07169318 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Recruiting | pH1N1 Blinded Challenge Study NCT07110532 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Active Not Recruiting | Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg NCT05569239 | Osivax | Phase 2 |
| Not Yet Recruiting | A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension NCT07113392 | Jiangxi Kvvit Pharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | Enhancing Maternal Vaccine Knowledge and Uptake: the InTroDuce-Programme Trial NCT06815250 | Universiti Putra Malaysia | N/A |
| Completed | Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Infl NCT06506812 | Tor Biering-Sørensen | Phase 4 |
| Active Not Recruiting | Pilot Influenza Challenge Study NCT07063849 | Daniel Hoft, MD, PhD | Phase 1 |
| Recruiting | SURVEILLANCE, ASSESSMENT AND DETECTION OF INFLUENZA ASSOCIATED RESPIRATORY INFECTIONS IN HIV POSITIVE AND NEGA NCT07030075 | Centre for Infectious Disease Research in Zambia | — |
| Recruiting | H5N1 Milk Detection Study NCT06850298 | Emory University | N/A |
| Active Not Recruiting | Human Infection Study of H3N2 Influenza in Healthy Adults NCT06972810 | University of Melbourne | N/A |
| Not Yet Recruiting | Routine Application of Point-of-care PCR Test to Identify and Direct Therapy for Acute Respiratory Infection i NCT06780566 | The University of Hong Kong | N/A |
| Recruiting | GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE NCT06620185 | Imperial College London | N/A |
| Withdrawn | Community-based Behavioral Intervention to Increase Vaccination Using MOST NCT06614361 | New York University | Phase 2 |
| Completed | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Va NCT06864143 | ModernaTX, Inc. | Phase 2 |
| Recruiting | Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2 NCT06848309 | Washington University School of Medicine | — |
| Completed | A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People NCT06821061 | BioNTech SE | Phase 1 / Phase 2 |
| Recruiting | A/Texas Flu Challenge NCT06753474 | Emory University | Phase 1 |
| Withdrawn | Lot Consistency Study of COVID-19 and Influenza Combination Vaccine NCT06482359 | Novavax | Phase 2 / Phase 3 |
| Not Yet Recruiting | Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza NCT06817096 | Azidus Brasil | Phase 3 |
| Recruiting | The Effects of Endotracheal Suctioning on Pain and Serum Markers NCT06692400 | Loma Linda University | N/A |
| Recruiting | Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules NCT06859333 | Valenta Pharm JSC | Phase 1 |
| Active Not Recruiting | A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years o NCT06744205 | Sanofi Pasteur, a Sanofi Company | Phase 1 / Phase 2 |
| Not Yet Recruiting | Oseltamivir and Baloxavir Marboxil for Prophylaxis Against Influenza Under a Hospital-based Setting NCT06762587 | Capital Medical University | N/A |
| Completed | A Prospective Epidemiological Study Evaluating Occurrences of Influenza-like Illness NCT06779981 | Osivax | — |
| Completed | MxA-Guided Antiviral Treatment in Respiratory Viral Infections NCT06668025 | Capital Medical University | N/A |
| Recruiting | Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza NCT06574503 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 3 |
| Recruiting | The Role of Cxcr4Hi neutrOPhils in InflueNza NCT06254313 | University Hospital, Bordeaux | — |
| Recruiting | COVID-19 Booster and IIV Schedule in Immunocompromised Hosts NCT06599658 | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 2 |
| Completed | Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19 NCT06694389 | ModernaTX, Inc. | Phase 3 |
| Completed | Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of NCT06641180 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Clinical Evaluation of the VitaSIRO Solo™ Respiratory Assay NCT06689423 | Credo Diagnostics Biomedical Pte. Ltd. | — |
| Recruiting | The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program NCT05832307 | University of Colorado, Denver | N/A |
| Completed | Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Particip NCT06774859 | Hoffmann-La Roche | Phase 3 |
| Completed | Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previous NCT06582277 | Osivax | Phase 2 |
| Completed | Revealing Protective Immunity to Influenza Using Systems Immunology NCT06501963 | Emory University | Phase 4 |
| Recruiting | CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools NCT06640387 | The Hospital for Sick Children | — |
| Completed | Text4Vax: Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-25 Season NCT06603090 | Columbia University | N/A |
| Completed | Nationwide Utilization of Danish Government Electronic Letter System for Confirming the Effectiveness of Behav NCT06600490 | Tor Biering-Sørensen | N/A |
| Recruiting | Clinical Trial Evaluating the Efficacy and Safety of Dexamethasone Compared to Placebo in Patients With Severe NCT06528444 | Instituto de Investigación Sanitaria y Biomédica de Alicante | Phase 3 |
| Completed | Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension NCT06643156 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 1 |
| Recruiting | High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients NCT05947071 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | The Interaction Between Mucosal Microbiota Colonization and the Immune Response to an Intranasal Influenza Liv NCT06609811 | Jiangsu Province Centers for Disease Control and Prevention | Phase 4 |
| Completed | Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications NCT06609460 | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Recruiting | Clinical Study on the Immune Response Characteristics of Novel Coronavirus and Influenza Virus Infection NCT06667063 | Zhongnan Hospital | — |
| Completed | Immunogenicity of Influenza Vaccinations NCT06518577 | Duke University | Phase 4 |
| Active Not Recruiting | Kaiser Permanente VACCination Improvement With Nudge-based CardiovAscular Targeted Engagement NCT06571747 | Kaiser Permanente | N/A |
| Completed | Influenza Reminder Text-Messaging NCT06587984 | Children's Hospital of Philadelphia | N/A |
| Completed | Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose L NCT06560151 | Biomedical Advanced Research and Development Authority | Phase 2 |
| Completed | Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years o NCT06507553 | Sanofi Pasteur, a Sanofi Company | Phase 1 |
| Terminated | Digital Storytelling to Reduce Pediatric Influenza Vaccination Disparities NCT06274359 | Denver Health and Hospital Authority | N/A |
| Completed | A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 ( NCT06508320 | ModernaTX, Inc. | Phase 2 |
| Recruiting | Dime La VerDAD: Verify, Debunk, and Disseminate NCT06417762 | University of Chicago | N/A |
| Completed | ACTIVATE in Public Housing NCT06075732 | Charles Drew University of Medicine and Science | N/A |
| Completed | First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influen NCT06460064 | Sumitomo Pharma Co., Ltd. | Phase 1 |
| Completed | A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and NCT06342349 | Shanghai Institute Of Biological Products | Phase 1 |
| Completed | Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adop NCT06229444 | Evidation Health | N/A |
| Withdrawn | A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza. NCT06163677 | Pfizer | — |
| Terminated | Evaluation of a Screen and Treat Protocol for Influenza NCT06207058 | Tricore, Inc | — |
| Recruiting | Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India NCT06168019 | Boston University | — |
| Completed | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate NCT06178991 | BioNTech SE | Phase 3 |
| Completed | Xofluza-Wearables Feasibility-Study NCT06161454 | Children's Hospital of Philadelphia | Phase 4 |
| Completed | A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Ag NCT06179446 | Pfizer | Phase 1 |
| Completed | COVID-19 Vaccine Uptake Amongst Underserved Populations in East London NCT05866237 | Queen Mary University of London | N/A |
| Recruiting | A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Tran NCT06094010 | Hoffmann-La Roche | Phase 3 |
| Unknown | Equity Evaluation of Fact Boxes on Informed COVID-19 and Influenza Vaccination Decisions - Study Protocol NCT06076421 | Harding Center for Risk Literacy | N/A |
| Completed | Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening NCT06124131 | Tulane University | N/A |
| Recruiting | Systems Investigation of Vaccine Responses in Aging and Frailty NCT05291676 | Yale University | Phase 2 |
| Active Not Recruiting | Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Th NCT05895955 | Mahidol University | Phase 1 / Phase 2 |
| Unknown | The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School St NCT06208683 | Sinovac Biotech Co., Ltd | Phase 4 |
| Unknown | Commercially Available Cannabis Products for Immune Support NCT05944705 | Center For Interventional Pain and Spine | — |
| Completed | Study to Assess the Effect of Multistrain Probiotic on the Immune Response to the Influenza Vaccination NCT06103994 | The Archer-Daniels-Midland Company | N/A |
| Completed | HD vs SD Quadrivalent Influenza Vaccine in Adults Aged 65 to 79 Years in Galicia NCT06141655 | Federico Martinón Torres | Phase 4 |
| Recruiting | Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies NCT04772170 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age NCT06097273 | ModernaTX, Inc. | Phase 3 |
| Recruiting | Bone Marrow and Peripheral Blood Immune Responses Study NCT05616546 | Emory University | Phase 4 |
| Active Not Recruiting | A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults NCT05945485 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Patient Portal Flu Vaccine Reminders (RCT 6) NCT06062264 | University of California, Los Angeles | N/A |
| Unknown | Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines NCT06091410 | Catholic Kwandong University | Phase 4 |
| Completed | Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations NCT06020118 | Duke University | Phase 4 |
| Completed | Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake A NCT06030739 | Tor Biering-Sørensen | N/A |
| Unknown | Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Pro NCT06259487 | Wroclaw Medical University | N/A |
| Completed | Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza NCT06183229 | POLYSAN Scientific & Technological Pharmaceutical Company | Phase 3 |
| Completed | Nationwide Utilization of Danish Government Electronic Letter System for Confirming the Effectiveness of Behav NCT06030726 | Tor Biering-Sørensen | N/A |
| Unknown | Effect of Health Education on Promoting Influenza Vaccination Health Literacy NCT06048406 | Sun Yat-sen University | N/A |
| Recruiting | Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years NCT06029933 | Kaiser Permanente | — |
| Completed | Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FL NCT05968989 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults NCT05972174 | ModernaTX, Inc. | Phase 1 / Phase 2 |
| Completed | Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and Influenza Treatment System With Machine Learn NCT06052527 | Lizora LLC | — |
| Completed | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healt NCT05868382 | ModernaTX, Inc. | Phase 2 |
| Active Not Recruiting | SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies NCT05765396 | The Geneva Foundation | — |
| Completed | Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactiva NCT05734040 | Osivax | Phase 2 |
| Unknown | Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza NCT03901001 | Chinese University of Hong Kong | Phase 3 |
| Unknown | Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and Pneu NCT03900988 | Chinese University of Hong Kong | Phase 3 |
| Completed | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults NCT05827926 | ModernaTX, Inc. | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults NCT05755620 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Unknown | Combined Molecular Testing for Influenza, SARS-CoV-2, and RSV RNA From Different Upper Airway Specimens. NCT05765838 | Rigshospitalet, Denmark | N/A |
| Recruiting | A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza NCT05648448 | University of Oxford | Phase 2 |
| Completed | DMID 21-0041; Influenza CVD 59000 NCT05666245 | University of Maryland, Baltimore | N/A |
| Completed | A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months NCT05645900 | Ab&B Bio-tech Co., Ltd.JS | Phase 3 |
| Completed | A Study of the GRIP Influenza and SARS-CoV-2 POC Assays NCT05674370 | Mayo Clinic | N/A |
| Unknown | Measure of Vaccine Effectiveness to Prevent Hospitalizations for Viral Respiratory Infections in Adults NCT05582239 | ANRS, Emerging Infectious Diseases | — |
| Completed | Uptake of the Childhood Live Attenuated Influenza Vaccine (LAIV) and Influenza-related Healthcare Resource Use NCT06077045 | AstraZeneca | — |
| Completed | A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine NCT05519839 | Novavax | Phase 2 |
| Unknown | Discover the Immune Signature of Sepsis Caused by Acute Pulmonary Infection: A Cohort Study NCT05612893 | Capital Medical University | — |
| Completed | Seasonal Influenza and Pneumococcal Vaccination in the Elderly NCT05661890 | Lokman Hekim University | — |
| Active Not Recruiting | Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2 NCT05040659 | Massachusetts General Hospital | — |
| Completed | Nudging Flu Vaccination by Making it Easy for Patients to Schedule a Flu Shot NCT05493787 | Geisinger Clinic | N/A |
| Recruiting | High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients NCT05215327 | Vanderbilt University Medical Center | Phase 2 |
| Active Not Recruiting | Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP NCT06054269 | Centers for Disease Control and Prevention | Phase 3 |
| Completed | Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuva NCT05608005 | Sanofi Pasteur, a Sanofi Company | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults NCT05606965 | ModernaTX, Inc. | Phase 2 |
| Unknown | Enhancing Protection Against Influenza and COVID-19 for Pregnant Women and Medically at Risk Children NCT05613751 | University of Adelaide | N/A |
| Completed | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RS NCT05585632 | ModernaTX, Inc. | Phase 1 |
| Completed | Performance Evaluation of the Lucira COVID-19 & Flu Test NCT06141824 | Lucira Health Inc | N/A |
| Completed | Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin NCT05581407 | LiteVax BV | Phase 1 |
| Withdrawn | Increasing COVID-19, Influenza, and Pneumonia Vaccine Uptake NCT04761692 | Charles Drew University of Medicine and Science | N/A |
| Active Not Recruiting | Immunity to Infection in Healthy Participants and Participants With Cancer NCT05787964 | University Hospital Tuebingen | — |
| Recruiting | Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA) NCT06160128 | VA Office of Research and Development | — |
| Completed | A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Sta NCT05517174 | Tor Biering-Sørensen | Phase 4 |
| Completed | Precision Vaccine Promotion in Underserved Populations NCT05537441 | University of Southern California | N/A |
| Completed | A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus NCT06385821 | NPO Petrovax | Phase 3 |
| Completed | Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake NCT05542004 | Tor Biering-Sørensen | N/A |
| Completed | Nudging Flu Vaccination in Patients at Moderately High Risk for Flu and Flu-related Complications NCT05509283 | Geisinger Clinic | N/A |
| Completed | Patient Portal Flu Vaccine Reminders_RCT 5 (LADHS) NCT05535777 | University of California, Los Angeles | N/A |
| Completed | The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults NCT05523089 | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Completed | Patient Portal Flu Vaccine Reminders (5) NCT05525494 | University of California, Los Angeles | N/A |
| Completed | High-risk Influenza Vaccine Alert NCT05492786 | Geisinger Clinic | N/A |
| Active Not Recruiting | Impact of High Dietary Fiber on Microbiome and Vaccine Responses NCT05565586 | M.D. Anderson Cancer Center | N/A |
| Completed | Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers NCT05558462 | Valenta Pharm JSC | N/A |
| Completed | Flu Shot Pre-visit Questionnaire NCT05508698 | Geisinger Clinic | N/A |
| Recruiting | Respiratory Virus Sampling and Repository NCT05266222 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute V NCT05544916 | Valenta Pharm JSC | Phase 3 |
| Completed | To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Inf NCT05474755 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 3 |
| Withdrawn | Proof of Concept Trial of Adjuvant Activity of SWE, a Squalene-based -Oil-in-water Emulsion NCT05035680 | Gates Medical Research Institute | Phase 1 |
| Unknown | Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chi NCT05494047 | Pontificia Universidad Catolica de Chile | Phase 3 |
| Completed | Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAP NCT06125717 | Vaxess Technologies | Phase 1 |
| Completed | Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine NCT05027932 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Recruiting | Influenza Human Challenge Model NCT05332899 | Emory University | Phase 1 |
| Completed | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 7 NCT05375838 | ModernaTX, Inc. | Phase 1 / Phase 2 |
| Completed | Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in He NCT05284799 | Osivax | Phase 2 |
| Unknown | Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children NCT05315024 | The University of Hong Kong | N/A |
| Terminated | Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza NCT05170009 | Weill Medical College of Cornell University | Phase 2 / Phase 3 |
| Completed | Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants NCT06118151 | Sanofi Pasteur, a Sanofi Company | Phase 1 |
| Unknown | National Vaccine Adverse Event Reporting Survey and Etiology NCT05095844 | Neuroganics LLC | — |
| Unknown | To Identify the Immunogenicity and Safety of QIV in Children Aged 3-8 Years NCT05389137 | Wuhan Institute of Biological Products Co., Ltd | Phase 4 |
| Completed | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults NCT05252338 | CureVac | Phase 1 |
| Active Not Recruiting | A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza NCT05160636 | Pfizer | — |
| Unknown | Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children NCT05739474 | St. Petersburg Research Institute of Vaccines and Sera | Phase 3 |
| Unknown | Study Evaluating the Efficacy and Safety of AV5080 in Patients With Uncomplicated Influenza NCT05093998 | Viriom | Phase 3 |
| Recruiting | Antibiotic Therapy in Viral Airway Infections NCT05045612 | University Hospital, Akershus | Phase 4 |
| Unknown | InFLUenza and the HEART An Investigation Into the Acute and Lasting Cardiac Effects of Influenza Infection NCT05084846 | University Hospital, Gentofte, Copenhagen | — |
| Completed | Use of Wearable Sensors for Early Detection and Tracking of Viral Respiratory Tract Infections NCT05290792 | Emily McDonald | N/A |
| Completed | A Prospective Epidemiological Cohort Study Evaluating Occurrences of Influenza-like Illness. NCT05184387 | Osivax | — |
| Completed | Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunt NCT05060887 | Osivax | Phase 2 |
| Completed | Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 NCT05781191 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Active Not Recruiting | Taxifolin/ergothioneine and Immune Biomarkers in Healthy Volunteers (TaxEr) NCT05190432 | University of Southampton | N/A |
| Completed | A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months NCT05212623 | Jiangsu Province Centers for Disease Control and Prevention | Phase 1 |
| Terminated | Patient Portal Flu Vaccine Reminders_RCT 4 NCT05052190 | University of California, Los Angeles | N/A |
| Recruiting | Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients NCT04712539 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis. NCT05069714 | Seoul National University Hospital | Phase 3 |
| Completed | A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or NCT05030324 | Valenta Pharm JSC | Phase 2 |
| Completed | Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. St NCT05048589 | Tor Biering-Sørensen | Phase 2 |
| Completed | Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX) NCT05082688 | Radboud University Medical Center | Phase 2 |
| Unknown | A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years NCT05144464 | Jiangsu Province Centers for Disease Control and Prevention | Phase 4 |
| Completed | A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years NCT05313893 | Jiangsu Province Centers for Disease Control and Prevention | Phase 4 |
| Completed | Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake NCT05009251 | National Bureau of Economic Research, Inc. | N/A |
| Completed | Lottery Incentive Nudges to Increase Influenza Vaccinations NCT05012163 | National Bureau of Economic Research, Inc. | N/A |
| Completed | Single Dose and Multiple Dose Safety, Tolerability, PK，and Food Effect Study，and Interaction With Oseltamivir NCT04982913 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Active Not Recruiting | Association Between Gut Microbiome and Dietary Determinants and Vaccine Response NCT05239403 | M.D. Anderson Cancer Center | — |
| Recruiting | Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination NCT04794829 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71 NCT04978454 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Pharmacokinetics of Voriconazole in Adult ECMO Patients NCT04868188 | University Hospitals, Leicester | — |
| Unknown | Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks NCT05012189 | Insight Therapeutics, LLC | Phase 4 |
| Completed | Assessment, Feedback, Incentive, Exchange (AFIX OB) A Customizable Quality Improvement Intervention to Increas NCT04678271 | Yale University | N/A |
| Completed | Comparison of ARDS COVID-19 (WHO) vs ARDS Influenza in the ICU NCT04941092 | Central Hospital, Nancy, France | — |
| Completed | First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated NCT04896086 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults NCT04782323 | Seqirus | Phase 2 |
| Terminated | Apple Respiratory Study NCT04912180 | Apple Inc. | — |
| Recruiting | B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults NCT04101838 | University of Alabama at Birmingham | Phase 4 |
| Completed | Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine NCT04801888 | Sinovac Research and Development Co., Ltd. | Phase 4 |
| Active Not Recruiting | Exercise and COVID-19 Viral T-cell Immunity NCT05019456 | University of Arizona | N/A |
| Completed | Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra NCT05308212 | St. Petersburg Research Institute of Vaccines and Sera | Phase 2 / Phase 3 |
| Unknown | Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Fo NCT04672577 | Patricia Schlagenhauf | — |
| Terminated | Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19) NCT04664075 | Imperial College London | — |
| Active Not Recruiting | High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients NCT04613206 | Vanderbilt University Medical Center | Phase 2 |
| Completed | A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza NCT04736758 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 2 |
| Completed | Effectiveness of Trivalent Influenza Vaccine (TIV) in Type 2 Diabetes Mellitus (T2DM) Patients With and Withou NCT06252051 | Universitas Padjadjaran | Phase 4 |
| Withdrawn | An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Prote NCT04806529 | Seqirus | Phase 2 / Phase 3 |
| Completed | Pediatric Second Influenza Dose Portal Reminder Recall NCT04668417 | University of California, Los Angeles | N/A |
| Completed | Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness NCT04610047 | Emergo Therapeutics, Inc. | Phase 2 |
| Completed | Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Ye NCT05312294 | St. Petersburg Research Institute of Vaccines and Sera | Phase 3 |
| Completed | Maternal Determinants of Immunity to Influenza NCT06716567 | Centre Hospitalier Universitaire Saint Pierre | Phase 4 |
| Completed | Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-Based Study Platform NCT04663776 | Boston Children's Hospital | — |
| Completed | Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years NCT04622592 | Medicago | Phase 1 / Phase 2 |
| Completed | Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine NCT04798677 | AB Biotek | N/A |
| Completed | Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF NCT04579250 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults NCT04576702 | Seqirus | Phase 2 |
| Completed | Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vac NCT05869201 | St. Petersburg Research Institute of Vaccines and Sera | Phase 2 / Phase 3 |
| Completed | The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata NCT04239521 | Momentum Data | — |
| Completed | Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness NCT04570904 | University of Leicester | — |
| Completed | Encouraging Flu Vaccination Among High-Risk Patients Identified by ML NCT04323137 | Geisinger Clinic | N/A |
| Active Not Recruiting | Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza NCT06286488 | Medical University of Warsaw | Phase 4 |
| Terminated | Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine NCT04544267 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Mo NCT04695717 | Vietnam Military Medical University | Phase 3 |
| Completed | Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- UCLA Portal R/R Influenza RCT 3 NCT04533685 | University of California, Los Angeles | N/A |
| Completed | Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection NCT04164212 | University of Alabama at Birmingham | Phase 4 |
| Completed | Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects NCT04729764 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 1 |
| Unknown | Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in H NCT04548518 | Mahidol University | Phase 3 |
| Completed | A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics NCT04603989 | Guangzhou Henovcom Bioscience Co. Ltd. | Phase 1 |
| Completed | Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants NCT04471038 | SAb Biotherapeutics, Inc. | Phase 1 |
| Unknown | Household Study of COVID-19, Influenza and RSV Burden, Transmission Dynamics and Viral Interaction in South Af NCT05277298 | National Institute for Communicable Diseases, South Africa | — |
| Completed | Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults NCT04439695 | KBio Inc | Phase 1 |
| Terminated | Innovative Tool to Limit Spread of COVID 19 in Residential Aged Care Facilities NCT04377165 | The University of Queensland | N/A |
| Withdrawn | Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza NCT03903718 | MedImmune LLC | Phase 2 |
| Unknown | COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial NCT04327791 | Bassett Healthcare | Phase 2 / Phase 3 |
| Completed | Audio Data Collection for Identification and Classification of Coughing NCT04326309 | HealthMode Inc. | — |
| Recruiting | The DETECT(Digital Engagement & Tracking for Early Control, & Treatment) Study NCT04336020 | Scripps Translational Science Institute | — |
| Completed | Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment NCT04365608 | Lazarski University | N/A |
| Completed | The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza NCT05089123 | St. Petersburg Research Institute of Vaccines and Sera | Phase 3 |
| Completed | Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling NCT04282135 | Klinikum Bayreuth GmbH | — |
| Completed | The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the NCT05317767 | St. Petersburg Research Institute of Vaccines and Sera | Phase 3 |
| Completed | Clinical Trial of Quadrivalent Influenza Virus Split Vaccine NCT04363359 | Shanghai Institute Of Biological Products | Phase 2 |
| Unknown | Incidence of Influenza Infections and Determination of Vaccination Coverage Rate Among Healthcare Workers NCT04223544 | Wroclaw Medical University | — |
| Completed | Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influen NCT04210349 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Suspended | Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults NCT04250311 | Materia Medica Holding | Phase 3 |
| Completed | Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After NCT04192500 | Osivax | Phase 2 |
| Unknown | Lung Bacteriobiota and Influenza Mortality NCT04131296 | University of Bordeaux | — |
| Completed | The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogen NCT05152017 | St. Petersburg Research Institute of Vaccines and Sera | Phase 1 |
| Terminated | Test-and-treat for Influenza in Homeless Shelters NCT04141917 | University of Washington | Phase 4 |
| Completed | Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 H NCT04144179 | Sanofi Pasteur, a Sanofi Company | Phase 1 |
| Completed | Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle NCT04141930 | University of Washington | Phase 4 |
| Completed | Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel NCT04523324 | Centers for Disease Control and Prevention | Phase 4 |
| Unknown | Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients NCT04143451 | The University of Hong Kong | Phase 3 |
| Completed | H1N1v Virus Challenge Study in Healthy Subjects NCT04044352 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- RCT 2 NCT04110314 | University of California, Los Angeles | N/A |
| Active Not Recruiting | Influenza IMPRINT Cohort: Defining the Impact of Initial Influenza Exposure on Immunity in Infants NCT05436184 | Children's Hospital Medical Center, Cincinnati | — |
| Completed | Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A NCT03969212 | Hoffmann-La Roche | Phase 3 |
| Completed | The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets NCT03898986 | Stanford University | Phase 1 |
| Completed | Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 NCT05832333 | Sanofi | — |
| Unknown | Retrospective Observational Study on the Epidemiological Characteristics of Influenza Patients NCT04110990 | University Hospital, Strasbourg, France | — |
| Completed | Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Qu NCT04109222 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Terminated | Response to Influenza Vaccine During Pregnancy NCT03888989 | Stanford University | Phase 1 |
| Completed | Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vac NCT04091880 | China National Biotec Group Company Limited | Phase 4 |
| Completed | Performance Feedback in Health Care NCT04579614 | Kaiser Permanente | N/A |
| Completed | Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects NCT04074928 | Seqirus | Phase 3 |
| Unknown | Recombinant Influenza Vaccination in U.S. Nursing Homes NCT03965195 | Insight Therapeutics, LLC | Phase 4 |
| Completed | Flublok or Fluzone With Advax-CpG55.2 or AF03 NCT03945825 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model NCT03883113 | Barinthus Biotherapeutics | Phase 2 |
| Withdrawn | Early Flu Shots in SOT NCT03327987 | University Health Network, Toronto | — |
| Completed | Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray NCT04146623 | Codagenix, Inc | Phase 1 |
| Completed | Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenz NCT03845231 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Phase 1 Study of ATR-002 NCT04385420 | Atriva Therapeutics GmbH | Phase 1 |
| Completed | Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vac NCT03777163 | Butantan Institute | Phase 4 |
| Withdrawn | Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood NCT03884296 | Stanford University | Phase 4 |
| Withdrawn | Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood NCT03898973 | Stanford University | Phase 4 |
| Terminated | Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults NCT03880474 | Barinthus Biotherapeutics | Phase 2 |
| Completed | Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine NCT03430089 | Sanofi Pasteur, a Sanofi Company | Phase 1 |
| Unknown | Oseltamivir Versus Paracetamol for Influenza-like Illness During the Influenza Season NCT03754686 | Rambam Health Care Campus | Phase 4 |
| Completed | Procalcitonin Role in Influenza Patients With Regard to Morbidity, Mortality and Antibiotic Use NCT04171128 | Ostfold Hospital Trust | — |
| Unknown | A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase Ⅱa Clinical Trial for the Effectiveness NCT03830684 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Completed | Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI NCT03830905 | PHARMENTERPRISES LLC | Phase 2 |
| Completed | Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Particip NCT03653364 | Hoffmann-La Roche | Phase 3 |
| Completed | Study of the Safety and Immunogenicity of NasoVAX Extension NCT03760549 | Altimmune, Inc. | — |
| Completed | Severe Influenza Trial of ARbidol NCT03787459 | Capital Medical University | Phase 3 |
| Unknown | Impact of Influenza/RSV PCR Point-of-care Testing in the Emergency Medical Service. NCT04048369 | University Hospital, Clermont-Ferrand | N/A |
| Completed | Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam NCT03765437 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Biomarkers for the Prognosis of Influenza in Children NCT03231995 | Hospices Civils de Lyon | N/A |
| Completed | Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Atte NCT03816878 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase I NCT03684044 | Hoffmann-La Roche | Phase 3 |